| Literature DB >> 29191619 |
Simon R Turner1, James M Isbell2.
Abstract
The National Lung Screening Trial established a survival benefit for lung cancer screening using low-dose computed tomography. In the wake of this trial several international bodies now recommend lung cancer screening. However, three main questions remain unanswered: Who is the optimal population for screening? How often should they be screened? For how long should screening be continued? We examine the results of the available randomized trials to address these questions.Entities:
Keywords: National Lung Screening Trial; low-dose computed tomography; lung cancer; screening
Year: 2017 PMID: 29191619 PMCID: PMC5971130 DOI: 10.1053/j.semtcvs.2017.11.008
Source DB: PubMed Journal: Semin Thorac Cardiovasc Surg ISSN: 1043-0679